A Phase 3 Randomized, Open-label, Active-comparator Controlled Clinical Study of Pembrolizumab Versus Platinum Doublet Chemotherapy in Participants With Mismatch Repair Deficient (dMMR) Advanced or Recurrent Endometrial Carcinoma in the First-line Setting
KEYNOTE-C93 (GOG-3064/ENGOT-en15)
NCT05173987
 Recruiting
|
CENTRE UNIVERSITAIRE DE SANTE MCGILL
 SITE GLEN
|
|
Phuong-Nam (Nathalie) Nguyen
514-934-1934 poste 31975
|
A Phase 3, Randomized, Double-Blind Study of Pembrolizumab Versus Placebo in Combination With Adjuvant Chemotherapy With or Without Radiotherapy for the Treatment of Newly Diagnosed High-Risk Endometrial Cancer After Surgery With Curative Intent
KEYNOTE-B21 / ENGOT-en11 / GOG-3053
NCT04634877
Recruiting
|
CENTRE UNIVERSITAIRE DE SANTE MCGILL
SITE GLEN
|
|
Phuong-Nam (Nathalie) Nguyen
514-934-1934 poste 31975
|
A Phase II, Single-Arm Study of Giredestrant in Patients With Grade 1 Endometrial Cancer
EndomERA
NCT05634499
Recruiting
|
CENTRE UNIVERSITAIRE DE SANTE MCGILL
SITE GLEN
|
|
|
A Phase 3, Randomized, Placebo-Controlled, Double-Blind, Multicenter Trial of Selinexor in Maintenance Therapy After Systemic Therapy for Patients With p53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma
XPORT-EC-042
NCT05611931
Recruiting
|
CENTRE UNIVERSITAIRE DE SANTE MCGILL
SITE GLEN
|
|
Phuong-Nam (Nathalie) Nguyen
514-934-1934 poste 31975
|
A Phase 3 Randomized, Open-label, Active-comparator Controlled Clinical Study of Pembrolizumab Versus Platinum Doublet Chemotherapy in Participants With Mismatch Repair Deficient (dMMR) Advanced or Recurrent Endometrial Carcinoma in the First-line Setting
KEYNOTE-C93 (GOG-3064/ENGOT-en15)
NCT05173987
Recruiting
|
CENTRE HOSPITALIER DE L'UNIVERSITE DE MONTREAL
|
|
France Gauthier
514-890-8000 poste 30921
|
ATARI: ATr Inhibitor in Combination With Olaparib in Gynaecological Cancers With ARId1A Loss
ATARI
NCT04065269
Recruiting
|
CENTRE HOSPITALIER DE L'UNIVERSITE DE MONTREAL
|
|
Lynda Abdelguerfi
514-890-8000 poste 30657
|
Multimodal PREhabilitation program for endometrial cancer patients. A feasibility study
PREPARE
n.d.
Recruiting
|
CENTRE HOSPITALIER DE L'UNIVERSITE DE MONTREAL
|
|
France Gauthier
514-890-8000 poste 30921
|
A Phase 3, Randomized, Placebo-Controlled, Double-Blind, Multicenter Trial of Selinexor in Maintenance Therapy After Systemic Therapy for Patients With p53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma
XPORT-EC-042
NCT05611931
Recruiting
|
CENTRE HOSPITALIER DE L'UNIVERSITE DE MONTREAL
|
|
Josée Tremblay
514-890-8000 poste 30637
|
A Phase III Randomized, Placebo-Controlled Study of Pembrolizumab in Addition to Paclitaxel and Carboplatin for Measurable Stage III or IVA, Stage IVB or Recurrent Endometrial Cancer
ENC.1
NCT03914612
Recruiting
|
CISSS DE LAVAL
HOPITAL DE LA CITE-DE-LA-SANTE
|
|
Solange Tremblay
450-668-1010 poste 23603
|
A Phase 3 Randomized, Open-label, Active-comparator Controlled Clinical Study of Pembrolizumab Versus Platinum Doublet Chemotherapy in Participants With Mismatch Repair Deficient (dMMR) Advanced or Recurrent Endometrial Carcinoma in the First-line Setting
KEYNOTE-C93 (GOG-3064/ENGOT-en15)
NCT05173987
Recruiting
|
CIUSSS DU CENTRE-OUEST-DE-L'ILE-DE-MONTREAL
HOPITAL GENERAL JUIF SIR MORTIMER B.DAVIS
|
|
|
Groupe d'étude en oncologie du Québec